Rentschler Biopharma and ATUM announced the signing of a full CDMO licensing agreement for the Leap-In Transposase® platform.
Under the terms of the agreement, ATUM will provide Rentschler Biopharma full access to its Leap-In Transposase® platform. The technology platform is an integrated solution combining proprietary re-coding algorithms, unique genetic vector elements as well as a transposon-based mechanism for efficient insertion of genetically stable elements into the genome. ATUM’s technology will enhance Rentschler Biopharma’s cell line development services and capabilities and complement the existing service offered via the CDMO’s strategic partner network.
Rentschler Biopharma and ATUM will be able to offer an additional service that will produce stable, high titer manufacturing cell lines, thereby supporting a growing number of organizations in moving their promising biopharmaceuticals to the market faster and with lower manufacturing risk than using alternative strategies. ATUM’s Leap-In Transposase® platform will complement Rentschler Biopharma’s recently implemented CHO GS KO platform for difficult-to-express proteins by providing innovative and tailored solutions to translate complex medical research into outstanding biopharmaceuticals. Rentschler Biopharma’s integrated platform process will be well suited for high-quality protein expression and allow clients access to further robust and flexible approaches to designer protein therapeutics.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“At Rentschler Biopharma, we are always looking for innovative solutions across the entire value chain – from concept to market – by establishing strategic and valuable partnerships. We are excited to combine our knowledge and in-house cell line development process with the deep expertise of ATUM, an industry leader in synthetic biology solutions for over a decade,” said Dr. Frank Mathias, CEO of Rentschler Biopharma. “We want the best for our clients, and with the addition of ATUM’s transformative Leap-In Transposase® platform to our current service portfolio, we will be able to further support our clients in the development and production of complex next-generation biotherapeutics.”
“Rentschler Biopharma and ATUM share a long-term, strong commitment to innovation and excellence,” said Dr. Jeremy Minshull, CEO of ATUM. “The Leap-In Transposase® technology is revolutionizing cell line development for simple as well as complex (multi-chain) therapeutic proteins and will provide Rentschler Biopharma stable, high-yield cell lines in very rapid timeframes. This capability adds another important instrument to their portfolio to accelerate time-to-market while maintaining product quality and reliability. We look forward to working with Rentschler Biopharma to support clients who are developing a wide variety of novel molecules.”